ConductScience.org, home

Paper2127348

In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.

Rolston KV and 5 others. Antimicrob Agents Chemother, 1990. Cited by 16 papers, by iCite.

Cite this record

ConductScience Library. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients. Papers, record 2127348. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2127348

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1990
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
16
iCite
Relative citation ratio, by iCite
0.95
iCite
Revised in PubMed
2021-05-26
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rolston KVK V
2Nguyen HH
3Messer MM
4LeBlanc BB
5Ho DHD H
6Bodey GPG P

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Infective AgentsMajor topic
BacteriaMajor topic
Bacterial InfectionsMajor topic
FluoroquinolonesMajor topic
NeoplasmsMajor topic
Ciprofloxacin
Fleroxacin
Gram-Negative Bacteria
Gram-Positive Bacteria
Humans
Microbial Sensitivity Tests

Source PubMed

Download CSV of topics

References12

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17447427Method of reliable determination of minimal lethal antibiotic concentrations.Antimicrob Agents Chemother1980https://conductscience.org/library/papers/7447427PubMed
23538962Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.Ann Intern Med1987https://conductscience.org/library/papers/3538962PubMed
33466563Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.Ann Intern Med1987https://conductscience.org/library/papers/3466563PubMed
43037899Norfloxacin for prevention of bacterial infections in granulocytopenic patients.Am J Med1987https://conductscience.org/library/papers/3037899PubMed
53284340Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis.Am J Med1988https://conductscience.org/library/papers/3284340PubMed
62393270In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.Antimicrob Agents Chemother1990https://conductscience.org/library/papers/2393270PubMed
72732120In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.J Antimicrob Chemother1989https://conductscience.org/library/papers/2732120PubMed
82802544In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2802544PubMed
92558617In vitro activity of AT-4140 against clinical bacterial isolates.Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2558617PubMed
102327763Pharmacokinetics of a novel quinolone, AT-4140, in animals.Antimicrob Agents Chemother1990https://conductscience.org/library/papers/2327763PubMed
112327768Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy.Antimicrob Agents Chemother1990https://conductscience.org/library/papers/2327768PubMed
122653217Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients.Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2653217PubMed

Download CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.

PMIDTitleJournalYearIn PapersSource
9210669Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.Antimicrob Agents Chemother1997https://conductscience.org/library/papers/9210669PubMed
8851609
Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.
Antimicrob Agents Chemother1996https://conductscience.org/library/papers/8851609PubMed
7601015Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.Drugs1995https://conductscience.org/library/papers/7601015PubMed
1906696In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.Antimicrob Agents Chemother1991https://conductscience.org/library/papers/1906696PubMed
1666499Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.Antimicrob Agents Chemother1991https://conductscience.org/library/papers/1666499PubMed
1503453In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.Antimicrob Agents Chemother1992https://conductscience.org/library/papers/1503453PubMed
1320362In vitro activity of sparfloxacin compared with those of five other quinolones.Antimicrob Agents Chemother1992https://conductscience.org/library/papers/1320362PubMed
1314175In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.Eur J Clin Microbiol Infect Dis1992https://conductscience.org/library/papers/1314175PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2127348

GET https://conductscience.org/api/papers/v1/2127348/authors